Suggestions

Du même auteur

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Archive ouverte | Nicolini, Franck Emmanuel | CCSD

International audience

Recommandations 2015 du France Intergroupe des Leucémies Myéloïdes Chroniques pour la gestion du risque d'événements cardiovasculaires sous nilotinib au cours de la leucémie myéloïde chronique

Archive ouverte | Rea, Delphine | CCSD

International audience. Tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein represent an outstanding progress in chronic myeloid leukemia and long-term progression-free survival has become a reality for a m...

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

Archive ouverte | Rea, Delphine | CCSD

International audience. Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatin...

Chargement des enrichissements...